BIOPHTA is a France-based early-stage biotech company focusing on the development of technology-backed eye treatment solutions disrupting retina and front-of-eye therapies. The company's patented ophthalmic insert technology can target many indications of allergic conjunctivitis, dry eye syndrome, cataracts, and age-related macular degeneration. Founded in 2020, the company has its headquarters in Paris, France.
read more..